These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 35115256)
1. Effects of androgen deprivation therapy on metabolic markers and bioelectrical impedance analyze in prostate cancer patients. Çakıcı MÇ; Can B; Kazan Ö; Efiloğlu Ö; Şendoğan F; Uçar T; Turan T; Yıldırım A Rev Int Androl; 2022; 20(2):96-101. PubMed ID: 35115256 [TBL] [Abstract][Full Text] [Related]
2. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523 [TBL] [Abstract][Full Text] [Related]
3. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer. Harrington JM; Schwenke DC; Epstein DR; Bailey DE Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236 [TBL] [Abstract][Full Text] [Related]
4. Long-term effects of androgen deprivation therapy in prostate cancer patients. Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048 [TBL] [Abstract][Full Text] [Related]
5. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of multidisciplinary interventions in preventing metabolic syndrome and improving body composition in prostate cancer patients treated with androgen deprivation therapy: A systematic review and meta-analysis. Yang U; Harikrishna A; Preda V; Chen J Clin Nutr ESPEN; 2023 Dec; 58():27-49. PubMed ID: 38057016 [TBL] [Abstract][Full Text] [Related]
7. Metabolic effects of androgen deprivation therapy. Choi SM; Kam SC Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932 [TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation therapy in localized prostate cancer. Current status and future trends. Gómez Rivas J; Fernandez L; Abad-Lopez P; Moreno-Sierra J Actas Urol Esp (Engl Ed); 2023 Sep; 47(7):398-407. PubMed ID: 37667894 [TBL] [Abstract][Full Text] [Related]
9. Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial. Usmani N; Ghosh S; Sanghera KP; Ong AD; Koul R; Dubey A; Ahmed S; Quon H; Yee D; Parliament M; Sivananthan G; Hunter W; Danielson B; Rowe L; McDonald M; Kim JO Int J Radiat Oncol Biol Phys; 2023 Feb; 115(2):317-326. PubMed ID: 35907513 [TBL] [Abstract][Full Text] [Related]
10. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Braga-Basaria M; Muller DC; Carducci MA; Dobs AS; Basaria S Int J Impot Res; 2006; 18(5):494-8. PubMed ID: 16617314 [TBL] [Abstract][Full Text] [Related]
11. Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up. Oka R; Utsumi T; Endo T; Yano M; Kamijima S; Kamiya N; Shirai K; Suzuki H Int J Clin Oncol; 2016 Apr; 21(2):389-396. PubMed ID: 26296528 [TBL] [Abstract][Full Text] [Related]
12. Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control. Ziaran S; Goncalves FM; Breza J World J Urol; 2013 Apr; 31(2):289-92. PubMed ID: 22898989 [TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. Shahani S; Braga-Basaria M; Basaria S J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064 [TBL] [Abstract][Full Text] [Related]
14. Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer. Mitsuzuka K; Kyan A; Sato T; Orikasa K; Miyazato M; Aoki H; Kakoi N; Narita S; Koie T; Namima T; Toyoda S; Fukushi Y; Habuchi T; Ohyama C; Arai Y; ; Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):57-62. PubMed ID: 26503109 [TBL] [Abstract][Full Text] [Related]
15. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer. Taaffe DR; Buffart LM; Newton RU; Spry N; Denham J; Joseph D; Lamb D; Chambers SK; Galvão DA BJU Int; 2018 Feb; 121(2):194-202. PubMed ID: 28872752 [TBL] [Abstract][Full Text] [Related]
16. Renal Function Improves After the Discontinuation of Androgen Deprivation Therapy in Japanese Patients With Prostate Cancer. Masuda H; Fujimoto A; Kanesaka M; Hou K; Suyama T; Araki K; Kojima S; Naya Y Anticancer Res; 2021 Sep; 41(9):4443-4446. PubMed ID: 34475067 [TBL] [Abstract][Full Text] [Related]
17. Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: Primary results from the real-life experience of ADT in Asia (READT) study. Wong CHM; Xu N; Lim J; Feng KK; Chan WKW; Chan MTY; Leung SC; Chen DN; Lin YZ; Chiu PKF; Yee CH; Teoh JYC; Huang CY; Yeoh WS; Ong TA; Wei Y; Ng CF Prostate; 2023 Jun; 83(8):801-808. PubMed ID: 36938957 [TBL] [Abstract][Full Text] [Related]
18. Depressive symptoms are found to be potential adverse effects of androgen deprivation therapy in older prostate cancer patients: A 15-month prospective, observational study. Zhang Z; Yang L; Xie D; Shi H; Li G; Yu D Psychooncology; 2017 Dec; 26(12):2238-2244. PubMed ID: 28474429 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial. Uth J; Hornstrup T; Christensen JF; Christensen KB; Jørgensen NR; Schmidt JF; Brasso K; Jakobsen MD; Sundstrup E; Andersen LL; Rørth M; Midtgaard J; Krustrup P; Helge EW Osteoporos Int; 2016 Apr; 27(4):1507-1518. PubMed ID: 26572756 [TBL] [Abstract][Full Text] [Related]
20. The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy. Morote J; Gómez-Caamaño A; Alvarez-Ossorio JL; Pesqueira D; Tabernero A; Gómez Veiga F; Lorente JA; Porras M; Lobato JJ; Ribal MJ; Planas J; J Urol; 2015 Jun; 193(6):1963-9. PubMed ID: 25541340 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]